2011
The role of GDC-0449, a hedgehog (Hh) pathway inhibitor, on epithelial–mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC) cells lines and its effect on erlotinib and cisplatin.
Maitah M, Ali S, LoRusso P, Sarkar F, Gadgeel S. The role of GDC-0449, a hedgehog (Hh) pathway inhibitor, on epithelial–mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC) cells lines and its effect on erlotinib and cisplatin. Journal Of Clinical Oncology 2011, 29: 10537-10537. DOI: 10.1200/jco.2011.29.15_suppl.10537.Peer-Reviewed Original Research
2010
A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients (pts) with advanced solid tumors.
Moldovan C, Soria J, LoRusso P, Guthrie T, Song C, Nguyen L, Martini J, Infante J, Burris H. A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients (pts) with advanced solid tumors. Journal Of Clinical Oncology 2010, 28: 3070-3070. DOI: 10.1200/jco.2010.28.15_suppl.3070.Peer-Reviewed Original Research